Akero Therapeutics, Inc.
DelistedCIK 1744659fmd_0TZFZDR9FSK8GKPQM4B2W1R4BJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2025, 31 periods
Latest annual · FY2024
Millions- Operating income
- (285)
- Net income
- (252)
Latest quarter · Q3 FY2025
Millions- Operating income
- (90)
- Net income
- (82)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2019 to FY2024
- n/m
Akero Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Operating income | -$285.4 million | -$172.9 million | 10-K 2025-02-28 · proof | |
| Net income | -$252.1 million | -$151.8 million | 10-K 2025-02-28 · proof | |
| Cash from operating activities | -$230.1 million | -$145.4 million | 10-K 2025-02-28 · proof | |
| Total assets | $825.9 million | $580.3 million | +42.3% | 10-K 2025-02-28 · proof |
| Total liabilities | $75.8 million | $45 million | +68.5% | 10-K 2025-02-28 · proof |
| Cash and cash equivalents | $340.2 million | $234.2 million | +45.3% | 10-K 2025-02-28 · proof |
- What was Akero Therapeutics, Inc.'s operating income in fiscal 2024?
- Akero Therapeutics, Inc. reported operating income of -$285.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -$172.9 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2025. SEC
- What was Akero Therapeutics, Inc.'s net income in fiscal 2024?
- Akero Therapeutics, Inc. reported net income of -$252.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -$151.8 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2025. SEC
- What was Akero Therapeutics, Inc.'s cash from operating activities in fiscal 2024?
- Akero Therapeutics, Inc. reported cash from operating activities of -$230.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -$145.4 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2025. SEC
- What are Akero Therapeutics, Inc.'s total assets?
- As of Dec 31, 2024, Akero Therapeutics, Inc. reported total assets of $825.9 million, against $580.3 million a year earlier (+42.3%). Source: the 10-K filed with the SEC on Feb 28, 2025. SEC
- What are Akero Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2024, Akero Therapeutics, Inc. reported total liabilities of $75.8 million, against $45 million a year earlier (+68.5%). Source: the 10-K filed with the SEC on Feb 28, 2025. SEC
- What are Akero Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Akero Therapeutics, Inc. reported cash and cash equivalents of $340.2 million, against $234.2 million a year earlier (+45.3%). Source: the 10-K filed with the SEC on Feb 28, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1744659&period_type=annual&limit=5"Information only, not investment advice.